Abstract
This paper compares the traditional drug development pathways with an innovative method for combining objectives and study designs within one trial. Evidence is offered in support of combining Phase II and Phase III trials for certain diseases and drugs. Newer regulations and guidelines are encouraging drug developers to be efficient and creative in conducting clinical trials.
Keywords
Get full access to this article
View all access options for this article.
References
1.Federal Register. 29540, May 30, 1997 .